HK Stock Market Move | ALEBUND-B(09637) Soars Over 46% as AP308 Receives FDA Clinical Clearance and Domestic Acceptance, Global Layout Value Expected to Materialize

ALEBUND-B(09637) surged over 46% in morning trading. As of press time, it was up 23.80% at HK$21.64, with turnover of HK$55.043 million. On the news front, Peking University First Hospital recently announced that the IND application for the next-generation AP308/PKU308, jointly developed by its Department of Nephrology and Alebund Pharmaceuticals for the treatment of IgA nephropathy, has been approved by the US FDA and will soon enter the first-in-human clinical study stage. On September 28, the application for AP308 for injection by Shanghai Alebund Pharmaceuticals Technology Co., Ltd. was accepted by the Center for Drug Evaluation of the National Medical Products Administration. Shenwan Hongyuan Group previously issued a research report stating that Alebund Pharmaceuticals is an innovative drug company focused on the CKD field, building a differentiated product matrix around disease-modifying therapy and complication management. It currently has 1 commercialized product and 7 innovative drug candidates, among which AP301, AP306 and AP303 have entered key development stages. The company integrates R&D, production and commercialization, and all pipeline assets are globally positioned, with full value realization expected after launch.